#USA #New York #Investor Rights #Bronstein Gewirtz #Vistagen Therapeutics

Vistagen Therapeutics Faces Class Action Lawsuit

Bronstein, Gewirtz & Grossman, LLC, a prominent investor-rights law firm, has initiated a class action lawsuit targeting Vistagen Therapeutics, Inc. (NASDAQ: VTGN) and several of its executives. This legal move aims to recuperate damages from alleged violations of federal securities laws. The class action is open to investors who purchased or obtained Vistagen's securities during the defined Class Period, which spans from April 1, 2024, to December 16, 2025.

Allegations and Background

The lawsuit claims that throughout this period, the defendants provided investors with misleading and overly optimistic statements about the development and potential success of the investigational drug, fasedienol. Concerted efforts to present the drug positively were apparently made despite significant and adverse information concerning the company's Phase 3 PALISADE-3 trial. The details in the complaint highlight key allegations, including that the defendants:

• - Made materially false claims regarding the drug's effectiveness, fueling investor confidence that was misplaced due to the lack of disclosed negative data.
• - Consciously withheld critical information about the trial's design and the results, misleading investors about the company's operational health and business outlook.
• - Continually pushed narratives that concealed the adverse findings of the PALISADE-3 study, which were essential for assessing the viability of their drug's future.

Next Steps for Affected Investors

Investors who believe they have been impacted by these alleged misrepresentations are urged to take action. Joining the class action is critical for those who wish to hold Vistagen accountable and seek compensation for possible losses suffered during the class period. Interested investors can find more information and the complaint details by visiting the firm’s website at bgandg.com/VTGN.

Investors must act swiftly, as the deadline to request the court to appoint them as lead plaintiff is March 16, 2026. It’s important to note that the opportunity for a financial recovery does not depend on serving as the lead plaintiff, a key aspect that encourages broader participation.

No Financial Risk for Investors

Bronstein, Gewirtz & Grossman represent shareholders on a contingency basis. This means that no legal fees or expenses are paid by the investors unless the case results in a successful recovery, either through a settlement or a court judgment. The firm's fees are typically collected from the total amount recovered, making this a low-risk avenue for investors.

Why Choose Bronstein, Gewirtz & Grossman?

Bronstein, Gewirtz & Grossman, LLC has a solid track record in representing investors in securities fraud cases and class actions. The firm has successfully recouped hundreds of millions of dollars for their clients across the nation. As stated by Peretz Bronstein, the firm's founding partner, "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace."

For more updates and legal information, investors are encouraged to follow the firm on LinkedIn, X, Facebook, or Instagram. Should you have further questions or need direct assistance, you can contact Peretz Bronstein or Nathan Miller directly at 917-590-0911.

Conclusion

The filing of this class action lawsuit signifies a crucial opportunity for investors of Vistagen Therapeutics to reclaim lost capital and seek justice for their grievances against misleading corporate practices. Taking proactive steps not only helps individual investors but also reinforces the accountability across the broader market landscape. Act now to ensure your voice is heard in the pursuit of the rightful justice and recovery that you deserve.